|
 |
|
|
|
READERSHIP & CIRCULATION |
|
Areas of work
Bioinformatics
Biotechnology
Biochemistry
Business development
Cell biology
Clinical research
Clinical trials
Drug discovery research
Genetics
Genomics
Immunology
Lab equipment
Microbiology
Molecular biology
Pharmacology
Proteomics
Toxicology
Tissue biology
Legal/regulatory
Intellectual property
Public policy/ethics
Private equity
Strategy & finance
Venture capital |
|
Geographical distribution
Europe
Africa
Asia
Asia Pacific
Middle East
North America
South America
Company type
Biopharmaceutical
Pharmaceutical Biotechnology
CRO
Government
ConsultantsUniversity/Institute
Investment management
Private equity
Job titles
CEO
CFO
CSO
MD
Product development
Purchasing
Business development
Sales & marketing |
|
|
|
|
|
ADVERTISING RATES |
|
WEB SITE FACILITIES |
| SIZE |
RATE
|
| FRONT COVER LOGO |
£2,450
|
| DOUBLE PAGE SPREAD |
£4,550
|
| SINGLE PAGE |
£2,750
|
| HALF PAGE |
£1,575
|
| QUARTER PAGE |
£795
|
OPPOSITE CONTENT
PAGES |
£3,750
|
| OPPOSITE EDITOR’S LETTER |
£3,750
|
| INSIDE FRONT COVER |
£4,950
|
| INSIDE BACK COVER |
£3,450
|
| OUTSIDE BACK COVER |
£5,750
|
|
|
1) Hyperlink from a relevant section of our website to client website
2) Banner and/or logo on our website (see below for banner specifications)
3) Client news page – to use for press releases during the duration of advertising.
4) Corporate profile up to 350 words
BANNER SPECIFICATIONS
GIF or JPEG (if static) or SWF (flash), 468 X 60 pix (centre or top) or 200 X 180 (right side)
All the above will be in place for as long as advertising runs |
|
|
|
|
|
MECHANICAL SPECIFICATIONS REPROGRAPHIC |
|
MECHANICAL DETAILS (IN MM) |
|
|
Type Size
|
Trim Size
|
Bleed Size
|
|
Double Page* |
273 x 396
|
297 x 420
|
303 x 426
|
|
One Page |
273 x 186
|
297 x 210
|
303 x 213
|
|
1/2 page (horizontal) |
135 x 186
|
148 x 210
|
151 x 213
|
|
1/2 page (vertical) |
273 x 92
|
297 x 105
|
303 x 108
|
|
1/4 page |
135 x 92
|
N/A
|
N/A
|
|
A. Electronic pictures or graphics can be supplied in the following formats:
1. Adobe Photoshop CS2 TIFF (*.tif), JPEG, PSD or EPS
2. Adobe Illustrator CS2 EPS
Electronic images/graphics must be supplied at high resolution (at least 300dpi)
Electronic images/graphics should be in CMYK colour.
Please do not send picture files embedded in Microsoft Word documents.
Please supply them as separate attachments.
B. Pictures can be supplied as good quality colour or black and white photographs
C. Client designed adverts should be supplied in one of the following ways:
1. QuarkXpress 6 (not Quark Passport). With relevant high resolution graphics and fonts also supplied.
2. Adobe Illustrator CS2. Images and graphics must be embedded. Fonts should be supplied if they are not embedded/converted to outline.
3. Adobe Acrobat PDF. Advert PDFs must be supplied optimised for high quality printing. All colours (inc. pictures) must be CMYK, no RGB or Pantone. They must include high resolution graphics (300dpi) and embedded fonts. Bleed adverts must include registration markings and bleed. We are unable to make ammendments to PDF files.
All adverts should be supplied with a colour copy of the advert. PDFs are supplied entirely at the client’s own risk and the publisher accepts no responsibility for any errors in printing.
Electronic files can be emailed to us. Larger files (above 10Mb) should be supplied to us on CD. |
|
|
 |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
PFIZER PRESENTS OVERALL SURVIVAL DATA FOR SUTENT™ VERSUS INTERFERON-ALFA
Chicago, 31 May 2008- Results from a landmark study have shown that sunitinib (SUTENT™)
has demonstrated overall survival greater than two years in patients with
metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer.
This is the first time overall survival data representing more than two years
has been achieved in the first line setting of mRCC, which is clinically
meaningful and reflective of major advances in the treatment of kidney
cancer.
More info >> |
|
|
